Collectively, these results implicated that AZ505 treatment may be protective against cisplatin-induced AKI by suppression of caspase-3 cleavage, reducing the BAX/BCL-2 ratio and inhibition of p53 phosphorylation. This evidence concerns the gene BCL2 and acute kidney injury.